The management of anti-neutrophil cytoplasmic antibody-associated vasculitis: what has changed in the last 10 years?
Suresh Ernest·British journal of hospital medicine (London, England : 2005)
The management of anti-neutrophil cytoplasmic antibody-associated vasculitis has substantially improved in the last decade. For the induction of remission, rituximab is increasingly used in place of cyclophosphamide, particularly for patients with proteinase 3 (PR3)-associated vasculitis or relapsing disease, and those…